Fed. Circ. Judge Probes 'Possible Mischief' In Biosimilar Law
A Federal Circuit judge questioned a lower court's decision allowing Amgen Inc. to launch a biosimilar of Genentech's blockbuster cancer drug Avastin, suggesting at a Wednesday hearing that the trial court's interpretation of the law...To view the full article, register now.
Already a subscriber? Click here to view full article